Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation

Dias, Joana; Lopes, Mariana Garcia Mendonça; Peleteiro, C.; Vicente, Gonçalo; Nunes, Telmo; Mateus, L.; Aires-da-Silva, Frederico; Tavares, Luís; Gil, Solange

doi:10.1016/j.vetimm.2019.109940

Cited by 8 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the implementation of such canine clinical trials is far from being an easy quest. It requires multiple organized efforts to validate the canine model, which still lacks a thorough characterization of the canine immune system and its effector cells and molecules, the evaluation of common tumor epitopes, the development of canine-specific/cross-reactive agents and the establishment of preclinical models for veterinary oncological settings ( 62 , 153 , 154 ). Furthermore, this also requires veterinary scientific community to join forces to implement diagnosis, staging and treatment response assessment optimization and standardization, to perform large and organized clinical trials and to achieve conformity when analyzing data ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, doxorubicin can cause a systemic inflammatory response in mice and human cancer patients, and contributes to adverse effects such as mucositis, cardiomyopathy and phlebitis (Mauldin et al., 1992 ; Ogilvie et al., 1989 ; Sauter et al., 2011 ; Tacar et al., 2013 ). IL‐6 and MCP‐1 were selected based on their role in the SASP and previous studies demonstrating altered expression in dogs with lymphoma, including elevated concentrations at the time of diagnosis (Campisi, 2013 ; Calvalido et al., 2016 ; Dias et al., 2019 ; Jin et al., 2016 ; Perry et al., 2011 ; Rolt et al., 2019 ). Potential explanations for elevated cytokines in dogs with lymphoma, includes primary production by neoplastic cells, and lymphoma‐induced changes to host immune and cytokine environment (Calvalido et al., 2016 ; Dias et al., 2019 ).…”

Section: Discussionmentioning

confidence: 99%

“…IL‐6 and MCP‐1 were selected based on their role in the SASP and previous studies demonstrating altered expression in dogs with lymphoma, including elevated concentrations at the time of diagnosis (Campisi, 2013 ; Calvalido et al., 2016 ; Dias et al., 2019 ; Jin et al., 2016 ; Perry et al., 2011 ; Rolt et al., 2019 ). Potential explanations for elevated cytokines in dogs with lymphoma, includes primary production by neoplastic cells, and lymphoma‐induced changes to host immune and cytokine environment (Calvalido et al., 2016 ; Dias et al., 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Serum IL‐6 and MCP‐1 concentrations in dogs with lymphoma before and after doxorubicin treatment as a potential marker of cellular senescence

Evans

Fenger

Ballash

et al. 2021

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Background: Chemotherapy can induce cellular senescence and a secretory phenotype characterized by an increased expression of inflammatory cytokines, such as IL-6 and MCP-1. Increased IL-6 and MCP-1 serum concentrations have been documented in dogs with lymphoma, but no studies have evaluated the effects of chemotherapy on cytokine concentrations.Objectives: To measure IL-6 and MCP-1 in 16 client-owned dogs with lymphoma, at baseline and before and after doxorubicin, as a potential marker for senescence and correlate cytokine concentrations with treatment response and toxicities.Methods: Serum IL-6 and MCP-1 concentrations at baseline, 0-h, 3-h, 6-h, 24-h and 1 week post doxorubicin were measured using a canine ELISA. We hypothesized that IL-6 and MCP-1 concentrations would increase following doxorubicin as a result of induction of cellular senescence.Results: IL-6 concentrations were unchanged from baseline to 0-h but significantly decreased 1 week post doxorubicin (p = 0.001) compared to 0-6 h (p = 0.045) and 24-h (p = 0.001) time points. MCP-1 concentrations significantly decreased from baseline to 0-h (p = 0.003). Compared to 0-6 h, MCP-1 concentrations transiently increased at 24h (p = 0.001) and decreased at 1 week (p = 0.014) post doxorubicin. Changes in IL-6 and MCP-1 concentrations did not correlate with leukocyte count, response to treatment or chemotherapy toxicities.Conclusions: Changes in IL-6 and MCP-1 concentrations did not support doxorubicininduced cellular senescence or correlate with leukocyte count, response to treatment or chemotherapy toxicity. However, our results suggest that remission status and doxorubicin treatment may influence cytokine concentrations and future studies are warranted to investigate the role of these cytokines as biomarkers.

show abstract

“…Another study has suggested that, in patients with adult T‐cell leukaemia/lymphoma, an increase in IL‐5 may be due to overproduction by the malignant T cells 34. In dogs, a study has shown evidence of local and systemic dysregulation in cytokine response in canine multicentric lymphoma 35. A different study showed that serum cytokine levels are higher in dogs with multicentric lymphoma when compared with healthy dogs and that that these levels differ between dogs with T‐cell and B‐cell lymphoma 36.…”

Section: Discussionmentioning

confidence: 99%

Canine acute eosinophilic dermatitis with oedema (Wells‐like syndrome) associated with T‐cell multicentric lymphoma

Alves¹,

Foale²,

Cerundolo³

et al. 2020

Vet Record Case Reports

View full text Add to dashboard Cite

A nine-year-old female neutered Boxer in clinical remission from T-cell multicentric lymphoma was presented for further investigation of multiple, non-painful, non-pruritic, oedematous, erythematous, serpiginous plaques. On examination, a very mild right superficial cervical lymphadenomegaly was also detected. Initial glucocorticoid treatment for a suspected hypersensitivity reaction was unsuccessful and the patient presented a week later with worsening of the dermatological signs. Cytology of peripheral lymph nodes was consistent with lymphoma relapse. Histopathology of skin biopsies was compatible with canine acute eosinophilic dermatitis with oedema, also known as Wells-like syndrome. Complete clinical resolution of the skin lesions and the peripheral lymphadenomegaly was achieved with six weeks of lomustine chemotherapy. To the authors’ knowledge, this is the first description of canine acute eosinophilic dermatitis with oedema suspected to be triggered by a multicentric lymphoma in a dog.

show abstract

Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation

Cited by 8 publications

References 50 publications

Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma

Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma

Serum IL‐6 and MCP‐1 concentrations in dogs with lymphoma before and after doxorubicin treatment as a potential marker of cellular senescence

Canine acute eosinophilic dermatitis with oedema (Wells‐like syndrome) associated with T‐cell multicentric lymphoma

Contact Info

Product

Resources

About